Association Between Atorvastatin Exposure and Low Folate Status: A Case-Control Study.

IF 0.8 Q4 PHARMACOLOGY & PHARMACY
Roberto Lozano, Irati Apesteguía, Alejandro Martínez
{"title":"Association Between Atorvastatin Exposure and Low Folate Status: A Case-Control Study.","authors":"Roberto Lozano,&nbsp;Irati Apesteguía,&nbsp;Alejandro Martínez","doi":"10.4103/jrpp.jrpp_66_22","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>The objective of this study is to assess the association between exposure to atorvastatin (ATV) and low-plasma folate (PF) status.</p><p><strong>Methods: </strong>The sample consisted of patients admitted to the internal medicine service of a basic general hospital, located in Zaragoza (Spain). We adopted a pharmacoepidemiological case-control study design. For this, the number of treatment days (TDs) of all the drugs part of their treatment during the study period was obtained from each patient in the sample. The cases were comprised by the number of patient's TDs for which PF ≤3 mg/dl and the controls by the number of patient's TDs for which PF >3 mg/dl. To measure the strength of the association, the odds ratios (ORs) were calculated. The Chi-square test, using the Bonferroni correction, was used to calculate the statistical significance.</p><p><strong>Findings: </strong>The sample consisted of 640 polymedicated patients. The mean PF obtained were 8.0 ± 4.6 mg/dl and 2.1 ± 0.6 mg/dl, for the cases and controls, respectively; the total number of TDs for the cases and controls were 7615 and 57899, respectively. We obtained a U-shaped curve when representing the dose of ATV against the corresponding ORs when comparing cases with control.</p><p><strong>Conclusion: </strong>Exposure to ATV at 10 or 80 mg is associated with an augmented risk of low folate status. We recommend implementing guidelines for mandatory folic acid fortification in patients exposed to ATV doses of 10 or 80 mg.</p>","PeriodicalId":17158,"journal":{"name":"Journal of Research in Pharmacy Practice","volume":"11 3","pages":"124-126"},"PeriodicalIF":0.8000,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/16/9d/JRPP-11-124.PMC10252577.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Research in Pharmacy Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/jrpp.jrpp_66_22","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: The objective of this study is to assess the association between exposure to atorvastatin (ATV) and low-plasma folate (PF) status.

Methods: The sample consisted of patients admitted to the internal medicine service of a basic general hospital, located in Zaragoza (Spain). We adopted a pharmacoepidemiological case-control study design. For this, the number of treatment days (TDs) of all the drugs part of their treatment during the study period was obtained from each patient in the sample. The cases were comprised by the number of patient's TDs for which PF ≤3 mg/dl and the controls by the number of patient's TDs for which PF >3 mg/dl. To measure the strength of the association, the odds ratios (ORs) were calculated. The Chi-square test, using the Bonferroni correction, was used to calculate the statistical significance.

Findings: The sample consisted of 640 polymedicated patients. The mean PF obtained were 8.0 ± 4.6 mg/dl and 2.1 ± 0.6 mg/dl, for the cases and controls, respectively; the total number of TDs for the cases and controls were 7615 and 57899, respectively. We obtained a U-shaped curve when representing the dose of ATV against the corresponding ORs when comparing cases with control.

Conclusion: Exposure to ATV at 10 or 80 mg is associated with an augmented risk of low folate status. We recommend implementing guidelines for mandatory folic acid fortification in patients exposed to ATV doses of 10 or 80 mg.

Abstract Image

阿托伐他汀暴露与低叶酸状态之间的关系:一项病例对照研究。
目的:本研究的目的是评估暴露于阿托伐他汀(ATV)和低血浆叶酸(PF)状态之间的关系。方法:以西班牙萨拉戈萨市某基础综合医院内科收治的患者为样本。我们采用药物流行病学病例对照研究设计。为此,从样本中每个患者获得研究期间所有药物部分治疗的治疗天数(TDs)。以PF≤3mg /dl的TDs数为例,以PF > 3mg /dl的TDs数为对照组。为了衡量这种关联的强度,我们计算了比值比(ORs)。采用卡方检验,采用Bonferroni校正,计算统计学显著性。结果:样本包括640例多药患者。患者和对照组的平均PF值分别为8.0±4.6 mg/dl和2.1±0.6 mg/dl;病例和对照组总td数分别为7615和57899。当将病例与对照进行比较时,我们得到了一条u形曲线,表示亚硝酸钠的剂量与相应的ORs。结论:暴露于10或80毫克的ATV与低叶酸状态的风险增加有关。我们建议对暴露于ATV剂量为10或80毫克的患者实施强制性叶酸强化指南。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Research in Pharmacy Practice
Journal of Research in Pharmacy Practice PHARMACOLOGY & PHARMACY-
自引率
0.00%
发文量
8
审稿时长
21 weeks
期刊介绍: The main focus of the journal will be on evidence-based drug-related medical researches (with clinical pharmacists’ intervention or documentation), particularly in the Eastern Mediterranean region. However, a wide range of closely related issues will be also covered. These will include clinical studies in the field of pharmaceutical care, reporting adverse drug reactions and human medical toxicology, pharmaco-epidemiology and toxico-epidemiology (poisoning epidemiology), social aspects of pharmacy practice, pharmacy education and economic evaluations of treatment protocols (e.g. cost-effectiveness studies). Local reports of medication utilization studies at hospital or pharmacy levels will only be considered for peer-review process only if they have a new and useful message for the international pharmacy practice professionals and readers.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信